10-K: Valuence Merger Corp. I Faces Delisting, Liquidation Risk

Valuence Merger Corp. I, a SPAC, faces substantial doubt about its ability to continue as a going concern after Nasdaq delisted its securities and significant shareholder redemptions reduced its trust account balance.

Summary

• Valuence Merger Corp. I is a blank check company formed to acquire a business in Asia (excluding China, Hong Kong, Macau) focused on life sciences or sustainable technology.
• The company's securities were delisted from Nasdaq on March 11, 2025, due to its failure to complete a Business Combination within 36 months of its IPO, and now trade on the OTC Pink market.
• Shareholders have approved multiple extensions to the Business Combination period, with the latest extending the deadline to May 3, 2026, and potentially up to March 3, 2027, contingent on monthly deposits by the Sponsor.
• Significant shareholder redemptions have occurred: 15,799,245 shares for $167,831,206 in May 2023, 4,343,316 shares for $49,900,380 in June 2024, and 1,404,164 shares for $17,565,141.25 in February 2026.
• As of December 31, 2025, the Trust Account held $23,218,530, with a per-share redemption value estimated at $12.43.
• The company reported a net income of $280,285 for the year ended December 31, 2025, primarily from interest earned on the Trust Account, offset by operating costs.
• A working capital deficit of $4,961,450 existed as of December 31, 2025, raising substantial doubt about the company's ability to continue as a going concern.
• The Sponsor and its affiliates have provided non-interest bearing convertible promissory notes totaling $2,264,148 as of December 31, 2025, and an additional $1,500,000 note in February 2026, to fund extensions and working capital.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the company's delisting, massive shareholder redemptions, and the explicit 'going concern' warning from its auditor, indicating severe operational and financial distress.

Positives

• The management team possesses extensive experience in strategic acquisitions, corporate divestitures, recapitalizations, growth equity, sustainable technology, and life sciences.
• The company has a clear geographic and sector focus on Asia (excluding China, Hong Kong, Macau) in life sciences and sustainable technology, which are identified as high-growth potential markets.
• The management team has a broad network of contacts and corporate relationships in Asia and North America, which is expected to enhance sourcing of merger opportunities.
• The Sponsor and its affiliates have consistently provided funding for extensions to the Business Combination period, demonstrating commitment to completing a transaction.

Negatives

• The company's securities were delisted from Nasdaq on March 11, 2025, due to failure to complete a Business Combination within the required timeframe, now trading on the OTC Pink.
• Significant shareholder redemptions have drastically reduced the funds available in the Trust Account, from an initial $226,702,619 to $23,218,530 as of December 31, 2025.
• The company has a working capital deficit of $4,961,450 as of December 31, 2025, and its independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has not yet identified a definitive target for a Business Combination, despite being in discussions with a potential target and having entered into a non-binding letter of intent.
• The company is subject to a mandatory liquidation and dissolution if a Business Combination is not completed by March 3, 2027, at the latest, which would result in no liquidating distributions for warrant holders.
• The 2024 SEC SPAC Rules, effective July 1, 2024, may impose additional disclosure requirements and increase potential liability, further complicating the Business Combination process.

Risks

• The company is a recently incorporated blank check company with no operating history or revenues, making it difficult to evaluate its ability to achieve its business objective.
• Public Shareholders may not have an opportunity to vote on the proposed Business Combination, limiting their influence on the investment decision.
• The ability of Public Shareholders to redeem shares for cash may make the company's financial condition unattractive to potential Business Combination targets.
• Failure to complete the initial Business Combination within the prescribed timeframe (up to March 3, 2027) will result in liquidation, with Public Shareholders receiving approximately $12.43 per share (as of Dec 31, 2025) or less, and no distributions for warrant holders.
• The company's existence is on a month-to-month basis, subject to Board discretion and monthly extension contributions from the Sponsor, which the Sponsor is not obligated to provide.
• Difficult market and geopolitical conditions may materially adversely affect the search for a Business Combination and any target business.
• The Sponsor, directors, and officers may purchase Public Shares or Public Warrants, potentially reducing the public float and influencing the Business Combination outcome.
• Third-party claims against the company could reduce the proceeds held in the Trust Account, leading to a lower per-share redemption amount for shareholders.
• The company may be deemed an investment company under the Investment Company Act, which could impose burdensome compliance requirements and restrict its activities.
• The company may seek acquisition opportunities in industries or sectors outside of its management's expertise, or with financially unstable or early-stage businesses, increasing risk.
• The company is not required to obtain an independent fairness opinion for a Business Combination unless with an affiliated entity or if the Board cannot independently determine fair market value.
• Compliance obligations under the Sarbanes-Oxley Act may increase the time and costs of completing an acquisition, especially with a target not in compliance.
• Issuance of additional Class A ordinary shares or preference shares to complete a Business Combination or under an employee incentive plan could dilute existing shareholders' interests.
• The Class A ordinary shares issuable upon exercise of warrants were not registered under federal or state securities laws, potentially making warrants worthless if registration is not in place.
• The grant of registration rights to Initial Shareholders and Private Placement Warrant holders may adversely affect the market price of Class A ordinary shares.
• Provisions in the Articles may inhibit a takeover, limiting the price investors might be willing to pay for Class A ordinary shares.
• The Initial Shareholders, owning approximately 75% of ordinary shares, can exert substantial influence on actions requiring a shareholder vote, including amendments to the Articles.
• The company may reincorporate in another jurisdiction, and foreign laws may govern future agreements, potentially limiting the ability to enforce legal rights.
• Acquisition opportunities in foreign countries are subject to political, economic, and other uncertainties, including regulatory compliance and currency fluctuations.
• Changes to laws or regulations, or a failure to comply, may adversely affect the business, including the ability to complete a Business Combination.
• Potential U.S. federal excise tax on stock buybacks could be imposed on redemptions if the company becomes a covered corporation, reducing cash available for a Business Combination.
• Exposure to liabilities under the Foreign Corrupt Practices Act could have a material adverse effect on the business, especially with operations in Asia.
• A Business Combination with a U.S. target company may be subject to U.S. foreign investment regulations and review by CFIUS, potentially leading to delays or prohibitions.

Future Outlook

The company is currently engaged in discussions with a potential target for a Business Combination and has entered into a non-binding letter of intent. However, no definitive agreement has been executed, and there is no assurance that such financing will be available on acceptable terms, if at all. The company has until May 3, 2026, to complete its initial Business Combination, which can be extended monthly until up to March 3, 2027, contingent on further contributions from the Sponsor. The company expects to incur significant costs in pursuit of its acquisition plans and faces substantial doubt about its ability to continue as a going concern if a Business Combination is not consummated by the deadline.

Management Comments

• Management believes that the company's success depends on the continued service of its officers and directors, at least until the initial Business Combination is completed.
• Management intends to concentrate efforts in identifying a potential Business Combination target based in Asia (excluding China, Hong Kong, and Macau) developing breakthrough technology in life sciences and/or advancing a platform for sustainable technology.
• Management believes that the net proceeds of the IPO and private placement warrants will be sufficient to allow the company to complete its initial Business Combination, but cannot assure that additional financing will be available if needed.
• Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Valuence Merger Corp. I's ongoing struggle to secure a Business Combination, coupled with its delisting from Nasdaq and significant shareholder redemptions, highlights the increasing challenges faced by SPACs in a more scrutinized and competitive market. The company's focus on Asia (ex-China, HK, Macau) in life sciences and sustainable technology aligns with growing global investment trends, yet its inability to close a deal underscores the difficulty of identifying and executing suitable transactions, especially for smaller SPACs with limited resources. The repeated extensions and reliance on sponsor funding are common indicators of SPACs nearing their liquidation deadlines, often leading to poor outcomes for public shareholders.

Comparison to Industry Standards

• The company's delisting from Nasdaq due to failure to complete a Business Combination within 36 months is a significant underperformance compared to successful SPACs that complete mergers within their initial or extended timelines.
• The high rate of shareholder redemptions (over 97% of initial public shares redeemed across multiple extension votes) is substantially higher than the average redemption rates seen in successful SPAC mergers, indicating a strong lack of confidence from public shareholders in the company's ability to find a suitable target or execute a value-creating transaction.
• The per-share redemption value of $12.43 as of December 31, 2025, while above the initial IPO price of $10.00, reflects the interest earned in the Trust Account rather than any operational success or value creation from a Business Combination, which is typical for liquidating SPACs.
• The company's working capital deficit and 'going concern' warning are stark contrasts to operating companies or successful SPACs that transition into operating entities with robust financial health.
• The reliance on convertible promissory notes from the Sponsor and its affiliates for extensions and working capital is a common SPAC practice but also signals the company's inability to generate sufficient operating capital or attract third-party financing without related-party support, unlike more robust SPACs that secure PIPE investments or other external funding for their mergers.

Corporate Governance

Related Party Transactions

• The Sponsor paid $25,000 for 5,750,000 Class B ordinary shares (Founder Shares) on October 4, 2021, which included shares subject to forfeiture.
• The Sponsor transferred 1,200,000 Founder Shares to Valuence Partners LP, an affiliated investment fund.
• The Sponsor and Valuence Partners LP purchased 6,666,667 Private Placement Warrants for $10,000,000 and an additional 267,995 Private Placement Warrants for $401,993.
• The Sponsor and Valuence Partners LP elected to convert 5,502,488 Class B ordinary shares into Class A ordinary shares on June 3, 2024.
• The Sponsor and Valuence Partners LP provided non-interest bearing, unsecured convertible promissory notes (Initial Extension Contribution Notes) totaling $2,264,148 as of December 31, 2025, for extensions and working capital.
• The Sponsor provided an additional non-interest bearing convertible promissory note (June 2024 Note) for $300,000 on June 4, 2024, for working capital.
• The Sponsor issued another non-interest bearing convertible promissory note (February 2026 Note) for $1,500,000 on February 27, 2026, for extensions, with no amounts drawn as of the filing date.
• The Sponsor and its affiliates are entitled to reimbursement of out-of-pocket expenses incurred in connection with identifying, investigating, negotiating, and completing a Business Combination.
• The Sponsor has agreed to be liable to the company for certain third-party claims that reduce the Trust Account below a specified threshold, subject to certain exceptions.

Stakeholder Impact

• Shareholders: Public shareholders have experienced significant redemptions, reducing their ownership and the company's capital. Those remaining face substantial risk of losing their investment if a Business Combination is not completed, as there will be no liquidating distributions for warrants and Class A shares may receive less than the estimated per-share amount.
• Warrant Holders: Will receive no liquidating distributions if the company fails to complete a Business Combination, making their warrants worthless.
• Sponsor/Affiliates: Have a strong incentive to complete a Business Combination to avoid losing their investment in Founder Shares and Private Placement Warrants, and to recover funds loaned for extensions and working capital. They hold significant voting power (approximately 75%) which can influence shareholder votes.
• Management: Their personal and financial interests may influence decisions regarding target selection and Business Combination terms, as their investment in Founder Shares and warrants would be worthless upon liquidation. They are also entitled to reimbursement of out-of-pocket expenses.
• Creditors: Face the risk that funds in the Trust Account may be insufficient to cover claims if waivers are not executed or are deemed unenforceable, potentially reducing the amount available for Public Shareholders upon liquidation.

Next Steps

• Continue identifying and evaluating prospective Business Combination candidates.
• Perform due diligence on prospective target businesses.
• Structure, negotiate, and consummate a Business Combination by the extended deadline of May 3, 2026, or potentially up to March 3, 2027, if further monthly extensions are approved and funded.
• The Board of Directors will continue to approve monthly extensions to the Combination Period, contingent on the Sponsor's contributions.
• If a Business Combination is not completed by the final deadline, the company will cease operations, redeem Public Shares, and liquidate.

Key Dates

Recommendation

The company faces severe existential threats, including delisting from Nasdaq, a 'going concern' warning from its auditor, and a rapidly dwindling Trust Account due to massive shareholder redemptions. The repeated extensions and reliance on related-party loans highlight a prolonged inability to secure a viable Business Combination. Public shareholders have already demonstrated a strong lack of confidence through redemptions. The risk of mandatory liquidation with no value for warrants and a potentially reduced return for shares is extremely high. Seasoned investors would recognize these as critical red flags signaling a high probability of capital loss.

Keywords

SPAC, Blank Check Company, Business Combination, Life Sciences, Sustainable Technology, Asia Investment, SEC Filing, 10-K, Delisting, Redemptions, Trust Account, Going Concern, Convertible Notes, Warrants, Corporate Governance, Risk Factors, Financial Reporting